Patterns of joint damage in severe haemophilia A treated with prophylaxis
暂无分享,去创建一个
S. Israels | V. Blanchette | M. Carcao | B. Feldman | R. Klaassen | S. Cloutier | G. Rivard | E. Paradis | E. Pullenayegum | A. Chan | N. Laferriere | John K Wu | M. Steele | R. Sinha | V. Price | Rachel Goren | Saunya Dover
[1] S. Israels,et al. Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study , 2020, Research and practice in thrombosis and haemostasis.
[2] M. Recht,et al. Early Prophylaxis Provides Continued Joint Protection in Severe Hemophilia A: Results of the Joint Outcome Continuation Study , 2018, Blood.
[3] P. Babyn,et al. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. , 2018, The Lancet. Haematology.
[4] M. Morfini. The History of Clotting Factor Concentrates Pharmacokinetics , 2017, Journal of clinical medicine.
[5] J. Oldenburg. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. , 2015, Blood.
[6] Benoit Liquet,et al. Estimation of extended mixed models using latent classes and latent processes: the R package lcmm , 2015, 1503.00890.
[7] A. Bianchi,et al. Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. , 2013, Blood.
[8] E. Berntorp,et al. Haemophilia and joint disease: pathophysiology, evaluation, and management , 2011, Journal of comorbidity.
[9] P. Helders,et al. Joint health and functional ability in children with haemophilia who receive intensive replacement therapy , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.
[10] E. Pullenayegum,et al. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian Hemophilia Primary Prophylaxis Study , 2011, Journal of thrombosis and haemostasis : JTH.
[11] L. Mantovani,et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) , 2011, Journal of thrombosis and haemostasis : JTH.
[12] L. Valentino,et al. Blood‐induced joint disease: the pathophysiology of hemophilic arthropathy , 2010, Journal of thrombosis and haemostasis : JTH.
[13] G. Dolan,et al. Changing patterns of bleeding in patients with severe haemophilia A , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.
[14] P. Lenting,et al. Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients , 2009, PloS one.
[15] M. Margaglione,et al. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype , 2008, Haematologica.
[16] Chih-Chien Yang,et al. Separating Latent Classes by Information Criteria , 2007, J. Classif..
[17] Alan R. Cohen,et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.
[18] M. Manco‐Johnson,et al. The Colorado Haemophilia Paediatric Joint Physical Examination Scale: normal values and interrater reliability , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.
[19] V. Blanchette,et al. Pharmacokinetics of recombinant factor VIII (Kogenate‐FS®) in children and causes of inter‐patient pharmacokinetic variability , 2006 .
[20] B. Feldman,et al. Hemophilia joint health score reliability study , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.
[21] P. Babyn,et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study , 2006, Journal of thrombosis and haemostasis : JTH.
[22] D. Grobbee,et al. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.
[23] D. Grobbee,et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. , 2005, Haematologica.
[24] M. Baiget,et al. The prothrombin 20210A allele influences clinical manifestations of hemophilia A in patients with intron 22 inversion and without inhibitors. , 2002, Haematologica.
[25] M. Manco‐Johnson,et al. Joint evaluation instruments for children and adults with haemophilia , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.
[26] J. Sixma,et al. The Half-life of Infused Factor VIII Is Shorter in Hemophiliac Patients with Blood Group 0 than in those with Blood Group A , 2000, Thrombosis and Haemostasis.
[27] H. Pettersson,et al. A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.
[28] In Colorado. , 1906 .